Table 3.

Treatment and outcome details in patients with COVID-19 related CVST undergoing mechanical thrombectomy

Cases	Current case	Case A	Case B
Treatment for COVID-19	Nil	Lopinavir - Ritonavir	Lopinavir - Ritonavir
Treatment for CVST (pharmacological)	Enoxaparin 60 mg S/C twice daily	Enoxaparin 70 mg S/C twice daily	Unfractionated heparin 1000 units per hour as continuous infusion
Treatment for CVST (surgical)	Mechanical thrombectomy of superior sagittal sinus	Mechanical thrombectomy of superior sagittal sinus and subsequent catheter based continuous r-TPA infusion at 2 mg/hour	Intrasinus thrombosis with r-TPA 20 mg slowly into superior sagittal sinus followed by mechanical thrombectomy; later underwent decompressive craniotomy on 8th day
Time duration between symptoms and endovascular therapy for CVST	On 5th day of admission	Within 24 hours	On 4th day of admission
Duration of admission	18 days	32 hours	10 days
Outcome	Discharged home with minimal deficits	Death after 32 hours of admission	Death after 10 days
Cause of death (if applicable)	N/A	Respiratory failure and cardiac arrest	Septic shock and DIC